कंपनी का अवलोकन
GeoVax Labs, Inc. operates as a clinical-stage biotechnology enterprise focused on the development of human vaccines and immunotherapies targeting infectious diseases and solid tumor cancers through novel proprietary platforms within the United States. The company functions within the broader healthcare sector and specifically the biotechnology industry, a domain characterized by high research intensity and long development cycles for preventive medical solutions such as vaccines against COVID-19 and other human immunodeficiency conditions. GeoVax Labs, Inc. maintains a market capitalization of $2.58M, generates annual revenue of $3.35M, and employs a workforce of 17 individuals to execute its strategic initiatives. The relatively modest market cap and revenue figures suggest that the company is in an early growth phase or a specialized niche, indicating a small-scale operation that relies heavily on successful clinical trial outcomes to expand its financial footprint and operational capabilities in the competitive vaccine landscape.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $3.35M, while the corresponding net income for the same period was -$25,309,002, and the EBITDA stood at -$25,469,526. The substantial disparity between the positive revenue of $3.35M and the significant negative net income reveals a cost structure dominated by high expenses, likely stemming from clinical trial costs, research and development expenditures, and operational overheads that exceed current revenue generation. The free cash flow is reported at -$14,961,973, which indicates that the company is consuming cash reserves to fund its operations and development pipeline rather than generating surplus cash for distribution or debt repayment. On the margin side, the gross margin is 0.0%, the operating margin is -761.6%, and the profit margin is 0.0%; these figures collectively indicate that the company is currently incurring heavy losses on every unit sold or project undertaken, typical for early-stage biotech firms before product commercialization. The balance sheet shows a cash position of $5.01M against zero debt, meaning the company holds liquidity without any interest-bearing obligations. Although the debt-to-equity ratio is listed as N/A due to the absence of debt, the presence of $5.01M in cash against no debt suggests a conservative balance sheet structure regarding leverage, free from the burden of financial distress associated with high interest payments. The current ratio is 3.57, which signifies that the company possesses more than three times the current assets needed to cover its short-term liabilities, reflecting strong short-term liquidity and the ability to meet immediate financial obligations without default risk. Finally, the return on equity is -377.4% and the return on assets is -178.9%, metrics that reveal management is currently generating negative returns on shareholder capital and invested assets, reflecting the heavy investment phase where earnings have not yet materialized to offset the significant capital deployed.
मूल्यांकन आकलन
The trailing twelve-month P/E ratio is N/A, while the forward P/E is listed as -1.35; the absence of a positive trailing P/E implies that the company has not yet achieved consistent profitability, whereas the negative forward P/E reflects market expectations of continued losses in the near term. The price-to-book ratio stands at 0.28, indicating that the company's market valuation is trading at a significant discount to its book value, suggesting the market prices in the high risk of the clinical-stage business model rather than a premium for assets. For alternative valuation perspectives, the price-to-sales ratio is 0.77 and the EV/EBITDA is 0.14; these metrics suggest that the market values the company based on its revenue generation potential rather than earnings, as the low EV/EBITDA multiple underscores the lack of current earnings power typical for pre-revenue or loss-making biotech entities. The stock has experienced significant volatility, with a 52-week high of $34.75 and a 52-week low of $1.14; depending on the current trading price relative to these extremes, the stock is currently trading at a level that reflects its extreme sensitivity to clinical news, though the specific percentage distance from the high or low fluctuates with daily market movements. The beta value is 3.81, which indicates that the stock's price volatility is nearly four times that of the broader market, highlighting the extreme risk profile and price swings inherent in small-cap biotechnology stocks.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, indicating that the company has not yet established a track record of comparable growth rates over a full year or that the data is insufficient to calculate year-over-year changes. Since the earnings growth cannot be calculated due to the negative net income, it is impossible to determine if earnings are growing faster or slower than revenue, but the negative earnings growth is implied by the substantial net loss. GeoVax Labs, Inc. is not a dividend payer, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%; consequently, the company reinvests all of its available earnings and cash flows back into research, development, and clinical trials rather than distributing income to shareholders. The overall growth and income profile for GeoVax Labs, Inc. is characterized by a lack of historical growth metrics and zero dividend income, relying entirely on capital appreciation potential driven by future clinical successes and regulatory approvals in the biotechnology sector.